Shannon Pemberton
Psychiatric/Mental Health · Barboursville, WVNPI 1346958279
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 199 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 30.1% of the total. Reporting peaked in 2024 at $2,068 and has fallen 94.5% since, to $115 in 2025. Among psychiatric/mental health clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Jazz Pharmaceuticals Inc.$604
- Alkermes, Inc.$449
- Axsome Therapeutics, Inc.$412
- Corium, LLC$276
- Harmony Biosciences LLC$270
- plus $975 from 12 others
What the payments were for
- Food & beverage$3,99493%
- Education$2787%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $1,286 |
| Jazz Pharmaceuticals Inc. | 34 | $604 |
| Alkermes, Inc. | 22 | $449 |
| Axsome Therapeutics, Inc. | 18 | $412 |
| Corium, LLC | 14 | $276 |
| Harmony Biosciences LLC | 10 | $270 |
| Teva Pharmaceuticals USA, Inc. | 19 | $249 |
| Otsuka America Pharmaceutical, Inc. | 12 | $207 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $98 |
| Ironshore Pharmaceuticals Inc. | 5 | $95 |
| Neurocrine Biosciences, Inc. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Lundbeck LLC | 2 | $30 |
| Johnson & Johnson | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Pfizer | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,272 in reported general payments places this provider in the 90th percentile of 142 psychiatric/mental health providers in West Virginia.
See all psychiatric/mental health providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 44 | $369,382 |
| VraylarCariprazine Hcl | 74 | $108,469 |
| SunosiSolriamfetol Hcl | 33 | $41,495 |
| RexultiBrexpiprazole | 27 | $39,153 |
| LybalviOlanzapine/Samidorphan Malate | 19 | $36,930 |
| NeuproRotigotine | 26 | $25,891 |
| CaplytaLumateperone Tosylate | 11 | $17,370 |
| Nurtec OdtRimegepant Sulfate | 14 | $13,868 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,377 |
| Gabapentin | 251 | $6,078 |
| Lurasidone Hcl | 22 | $5,307 |
| Armodafinil | 51 | $4,002 |
| Alprazolam | 543 | $3,753 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 112 | $3,624 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 13 | $3,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $82 | $369,38244 claims |
| AbbVieVraylar | $1,286 | $108,46974 claims |
| Axsome Therapeutics, Inc.Sunosi, Auvelity | $412 | $52,87244 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $207 | $39,15327 claims |
| Alkermes, Inc.Lybalvi | $449 | $36,93019 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $56 | $17,37011 claims |
| PfizerNurtec Odt | $18 | $13,86814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 142 psychiatric/mental health providers in West Virginia.
Other psychiatric/mental health in Barboursville
- Jeremy SchreiberWheeling$1.7M
- Kimberly RittenhouseParkersburg$7K
- Michael SkaggsRipley$7K
- Larry RobertsonHuntington$6K
- Gwendolyn HuffmanSummersville$6K
- Summer DevolParkersburg$5K
- Osric Malone-PrioleauSaint Marys$5K
- Mercedes WeikleFort Gay$5K
- Cathy McGeeParkersburg$4K
- Ashley ParlierBeckley$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.